Navigation Links
Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Date:4/25/2012

SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Aethlon Medical was originally formed to advance a medical device technology that targeted the removal of harmful metals from circulation.  At the time, our strategy to treat infectious disease was a mere seed of thought and we certainly didn't envision the opportunities that would emerge in cancer and sepsis.  Since those early days, Marc Robins has witnessed both the setbacks and advances in our quest to create innovative therapies to combat life-threatening conditions.

I am pleased to advise you that Marc has agreed to work with us to expand the awareness of our endeavors within the financial and medical community.  Additionally, he will provide our shareholders with an additional channel of communication.  Marc's unique understanding of medical technology (including the medical devices in our therapeutic pipeline) and the financial markets will help to ensure our message is properly communicated.  He is also a passionate AEMD shareholder with 35 years of experience in discovering and investing in micro-cap medical technology organizations.  Marc was a "Special Situation" columnist at FORBES magazine, the founding publisher of the The Red Chip Review, an analyst at E.F. Hutton, and a principal at The Robins Group, LLC, an institutional investment banking firm that once managed a financing that helped us advance clinical programs. Marc can be reached at (877) 276-2467 or by email at mr@aethlonmedical.com.

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
3. Aethlon Medical Establishes Sepsis & Inflammation Scientific Advisory Board
4. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
5. Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
6. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
7. Aethlon Medical Releases Shareholder Letter
8. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
9. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
10. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
11. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)...   , Total ... Consumable Sales  Clinical sales grow 16% year-over-year  ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... first quarter ended March 31, 2016 and provided an ... commercial strategy. First Quarter 2016 Revenue Results ...
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... that infants born with severe congenital diaphragmatic hernia have better survival rates if ... congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is ... pressure on the armpits, the M+D Crutch evenly distributes body weight from the elbow ... and hands when using the crutches than with other crutches. , Co-founders Max and ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):